Pauline Gee, Ph.D.
Formerly with Sciona, Inc.

Pauline Gee, PhD, was the former Chief Technical Officer with Sciona, Inc. She led genetic testing and regulatory affairs at Sciona, a health and wellness company that personalizes lifestyle and nutritional solutions based on an individual’s genetic variations.  Pauline was awarded the 2005 PolyPops Foundation Award for innovative applications in the area of microplate development and design by the Society of Biomolecular Sciences. Pauline was Vice President and General Manager, BioSystems Division of CeMines, Inc. responsible for commercializing protein biomarkers for early detection of cancer. Previously, Pauline was Vice-President of Predictive Biology at MDS Pharma Services where she led the company's chemogenomics and toxicogenomics efforts, representing MDS Pharma Services in its alliance with Iconix Pharmaceuticals. Before joining MDS Pharma Services, Pauline was President and CEO of Xenometrix, Inc., a public company that pioneered gene expression profiling to describe cellular responses to compounds and developed HTS Ames testing for mutagenicity. She brought Xenometrix to profitability which won Deloitte and Touchè Fast 50 Awards for two years before merging the company with Discovery Partners International, Inc. Pauline Gee, Ph.D. has served as Vice President Toxicology at Discovery Partners International after integrating Xenometrix’s operations in May, 2001. 

Pauline earned a doctorate in neurochemistry and B.S. degree in kinesiology/marine biology from Simon Fraser University, in British Columbia, Canada. As a Medical Research Council Fellow, she analyzed oxidized DNA bases and developed and patented DNA base-specific Ames strains while at the University of California Berkeley, and was the first to demonstrate DNA repair in differentiated neurons while at Stanford University.